マイクロフルイディクスの世界市場 - 2025年～2033年

マイクロフルイディクスの世界市場は、2024年に283億8,000万米ドルに達し、2032年には739億7,000万米ドルに達すると予測され、予測期間2025年～2033年に12.6％のCAGRで成長すると予測されています。

マイクロフルイディクスは、微小流路を流れる流体の挙動と、流体が流れたり閉じ込められたりするチャンバーや流路を含む微小化されたデバイスを製造する技術を研究しています。この分野の特徴は、一般的にマイクロリットル（10^-6リットル）からフェムトリットル（10^-15リットル）までの非常に小さな体積の流体に焦点を当てていることです。

マイクロフルイディクスは、マイクロ流体コンポーネントとマイクロ流体デバイスで構成されています。マイクロ流体コンポーネントは、マイクロスケールで少量の流体を操作・分析するために設計されたマイクロ流体システムの不可欠な部品です。マイクロフルイディクスデバイスは、マイクロチャンネルとチャンバーのネットワークを使用して、少量の流体を操作、制御、分析するように設計された高度なシステムです。

マイクロフルイディクス市場の成長を牽引するのは、業界の主要企業による調査活動と革新的なプラットフォームのイントロダクションです。例えば、インドは2023年2月、mRNAワクチンの迅速な前臨床開発専用に設計された初のマイクロ流体プラットフォームを導入し、ワクチン開発に大きな進展をもたらしました。この革新的なプラットフォームは、迅速な開発タイムラインと感染症に対する有効性で知られるmRNAワクチンの開発・試験プロセスを合理化することを目的としています。これらの要因が、世界のマイクロフルイディクス市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

ポイントオブケア検査（POCT）需要の増加

ポイントオブケア検査（POCT）に対する需要の高まりは、世界のマイクロフルイディクス市場の成長を大きく後押ししており、市場予測期間中も牽引役となることが予想されます。

ポイントオブケア検査（POCT）は、患者の診療現場で直接迅速な診断結果を提供できるため、臨床現場でますます不可欠になっています。この機能は、従来の検査室へのアクセスが制限される可能性のある救急医療や地方のヘルスケア環境では特に重要です。マイクロ流体デバイスはこの動向の中心であり、タイムリーな診断と治療に不可欠な最小限のサンプル量で迅速かつ正確な検査を可能にします。

ヘルスケアシステムが効率向上とコスト削減に努める中、ポイントオブケア検査（POCT）の需要が急増しています。この動向は、マイクロフルイディクスが従来の検査室以外で実施可能な迅速診断を提供し、患者ケアと業務効率を変革する能力によるところが大きいです。

さらに、業界の主要企業による調査活動や提携・協力がマイクロフルイディクス市場の成長を後押ししています。2024年8月のPIBニュースによると、研究者はウェアラブルアプリケーションに適した効率的でコスト効率の高い圧電デバイスを作るために重要な、高い電気活性（EA）相を持つ微小球の製造を可能にする液滴マイクロフルイディクス技術を開発しました。この進歩は、様々な生理学的信号をモニターする自己発電型センサーへの道を開くものとして重要です。

同様に、2023年4月、モルビオ・ダイアグノスティックスとシグテュプルは、人工知能（AI）や機械学習（ML）などの先端技術を活用した次世代POC（ポイント・オブ・ケア）診断装置の開発で協業します。

SigTuple社は、AIとマイクロフルイディクス技術の専門知識をこの提携にもたらします。AIとMLをPOCデバイスに組み込むことで、この提携は診断精度とスピードの向上を目指します。同社は、AI、ロボット工学、マイクロフルイディクスを活用して、十分なサービスを受けていない地域でも展開できるインテリジェントな診断ソリューションを生み出すというビジョンを掲げて設立されました。このアプローチは、特に従来の検査施設が不足している地域におけるヘルスケアへのアクセスにおける重大なギャップに対処するものです。これらすべての要因がマイクロフルイディクスの世界市場を促進します。

さらに、慢性疾患の罹患率の上昇と技術の進歩は、予測期間中にマイクロフルイディクス市場を促進すると予想される要因です。

高い研究開発コスト

研究開発コストの高さは、世界のマイクロフルイディクス市場の成長を妨げます。マイクロ流体製造および研究開発施設の設置に必要な多額の初期投資は、特に発展途上地域の企業にとって大きな障壁となります。マイクロフルイディクスには、流体を微細なスケールで操作するための高度な機械や技術が必要であり、これには高価な製造ツール、クリーンルーム環境、高解像度のイメージングシステムなどが含まれます。

例えば、マイクロ流体ラボのセットアップ費用は、使用する機器や材料にもよるが、一般的に約30,000ドルから65,000ドルです。このコストには、効果的なマイクロ流体研究開発に必要ないくつかの必須コンポーネントが含まれています。

製造中の汚染を防ぐためにクリーンルームの条件が必要なため、セットアップコストはさらに上昇し、資金力の乏しい中小企業が市場に参入するのは難しくなります。さらに、マイクロ流体技術は複雑であるため、工学、物理学、化学、生物学など、さまざまな分野にまたがる高度な技術を持った人材が必要とされます。このような専門知識の採用や訓練には時間とコストがかかり、設備投資もかさみます。これらすべての要因がマイクロフルイディクス市場の妨げになると予想されます。このように、上記の要因は世界のマイクロフルイディクス市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • ポイントオブケア検査（POCT）の需要増加
  • 抑制要因
    • 研究開発費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• マイクロ流体ベースのデバイス
• マイクロ流体コンポーネント
  • マイクロ流体チップ
  • マイクロポンプ
  • マイクロニードル
  • その他
• その他

第7章 材料別

• ポリマー
• シリコン
• ガラス
• その他

第8章 用途別

• ドラッグデリバリー
• ポイントオブケア診断
• 医薬品およびバイオテクノロジー調査
  • ハイスループットスクリーニング
  • プロテオミクス
  • ゲノミクス
  • 細胞ベースのアッセイ
  • キャピラリー電気泳動
  • その他
• 臨床診断
• その他

第9章 エンドユーザー別

• 病院および診断センター
• 学術研究機関
• 製薬・バイオテクノロジー企業

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• PerkinElmer
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Standard BioTools（Fluidigm Corporation）
• Merck KGaA
• Sphere Fluidics.
• uFluidix
• Emulate Inc.

第13章 付録

The global microfluidics market reached US$ 28.38 billion in 2024 and is expected to reach US$ 73.97 billion by 2032, growing at a CAGR of 12.6 % during the forecast period 2025-2032.

Microfluidics studies the behavior of fluids flowing through micro-channels and the technology that involves manufacturing microminiaturized devices containing chambers and channels through which fluids flow or are confined. This field is characterized by its focus on very small volumes of fluids, typically ranging from microliters (10^-6 liters) to femtoliters (10^-15 liters).

Microfluidics consists of microfluidic components and microfluidic devices. Microfluidic components are integral parts of microfluidic systems designed to manipulate and analyze small volumes of fluids at a microscale. Microfluidics devices are advanced systems designed to manipulate, control, and analyze small volumes of fluids using networks of microchannels and chambers.

Key players in the industry research activities and the introduction of innovative platforms drive the microfluidics market growth. For instance, in February 2023, India made a significant advancement in vaccine development by introducing its first microfluidic platform designed specifically for the rapid preclinical development of mRNA vaccines. This innovative platform aims to streamline the process of creating and testing mRNA vaccines, which are known for their quick development timelines and effectiveness against infectious diseases. These factors have driven the global microfluidics market expansion.

Market Dynamics: Drivers & Restraints

Increasing Demand for Point-of-Care Testing (POCT)

The increasing demand for point-of-care testing (POCT) is significantly driving the growth of the global microfluidics market and is expected to drive throughout the market forecast period.

Point-of-care testing (POCT) is increasingly vital in clinical settings due to its ability to deliver rapid diagnostic results directly at the site of patient care. This capability is particularly crucial in emergency and rural healthcare environments, where traditional laboratory access may be limited. Microfluidic devices are central to this trend, enabling quick, accurate testing with minimal sample volumes, which is essential for timely diagnosis and treatment.

As healthcare systems strive to enhance efficiency and reduce costs, the demand for point-of-care testing (POCT) has surged. This trend is largely due to the ability of microfluidics to provide rapid diagnostics that can be performed outside traditional laboratory settings, thereby transforming patient care and operational efficiency.

Furthermore, key players in the industry research activities, and partnerships & collaborations, would drive this microfluidics market growth. As per PIB news in August 2024, researchers have developed a droplet microfluidics technology that enables the production of microspheres with a high electroactive (EA) phase, which is crucial for creating efficient and cost-effective piezoelectric devices suitable for wearable applications. This advancement is significant as it paves the way for self-powered sensors that monitor various physiological signals.

Similarly, in April 2023, Molbio Diagnostics and SigTuple are collaborating to develop next-generation point-of-care (POC) diagnostic devices that leverage advanced technologies such as artificial intelligence (AI) and machine learning (ML).

SigTuple brings expertise in AI and microfluidics technologies to the partnership. By incorporating AI and ML into the POC devices, the collaboration seeks to improve diagnostic accuracy and speed. The company was founded with the vision of using AI, robotics, and microfluidics to create intelligent diagnostic solutions that can be deployed in underserved areas. This approach addresses critical gaps in healthcare access, particularly in regions where traditional laboratory facilities are scarce. All these factors demand the global microfluidics market.

Moreover, the rising incidence of chronic diseases and technological advancements are the factors expected to drive the microfluidics market over the forecast period.

High Research and Development Costs

The high research and development costs will hinder the growth of the global microfluidics market. The substantial initial investment needed to set up microfluidic manufacturing and R&D facilities creates a significant barrier for companies, especially in developing regions. Microfluidics requires advanced machinery and technology to manipulate fluids at a microscopic scale, which includes costly fabrication tools, cleanroom environments, and high-resolution imaging systems.

For instance, the setup cost for a microfluidic lab typically ranges from approximately $30,000 to $65,000, depending on the equipment and materials used. This cost encompasses several essential components necessary for effective microfluidic research and development.

The necessity for cleanroom conditions to prevent contamination during production further escalates setup costs, making it difficult for smaller firms with limited financial resources to enter the market. Additionally, the complexity of microfluidic technologies demands a highly skilled workforce across various disciplines, including engineering, physics, chemistry, and biology. Recruiting and training such expertise is both time-consuming and expensive, contributing to high capital expenditures. All these factors are expected to hamper the microfluidics market. Thus, the above factors could be limiting the global microfluidics market's potential growth.

Segment Analysis

The global microfluidics market is segmented based on product type, material, application, end-user, and region.

Product Type:

The microfluidic components segment is expected to dominate the global microfluidics market share

The microfluidic components segment holds a major portion of the global microfluidics market share and is expected to continue to hold a significant portion of the global microfluidics market share during the forecast period.

Microfluidic components are essential elements in the design and functionality of microfluidic systems, which are increasingly utilized across various fields such as biomedical research, diagnostics, and chemical synthesis. These components enable the manipulation, mixing, and analysis of fluids at a microscale, providing significant advantages over traditional methods.

The microfluidic component consists of microfluidic chips, micro pumps, and others. Microfluidic chips are the foundational elements of microfluidic systems. They consist of a network of microchannels and chambers that facilitate fluid manipulation.

Micropumps are essential devices within microfluidic systems that control the movement of fluids through the microchannels. These pumps enable accurate dosing and transport of liquids, which is crucial for maintaining precise flow rates during experiments. They can be pressure-driven or utilize other mechanisms such as electrokinetic forces to move fluids.

Furthermore, key players in the industry product launches and manufacturing facilities that would propel this segment's growth in the microfluidics market. For instance, in September 2022, Dolomite Bio is launching a compact, affordable microfluidic system for custom microfluidic and genomics research. This new system combines the microfluidic technology underlying their Nadia Instrument, with the customizable parameters of the Nadia Innovate. It grants access to the custom microfluidic protocol development without the necessity of a large capital outlay.

Similarly, in January 2024, uFluidix made significant strides in the manufacturing of thermoplastic microfluidic chips over the past year. The company has successfully doubled its manufacturing capacity and is now focusing on optimizing new process variables to enhance production efficiency and product quality. This initiative is particularly relevant as the demand for microfluidic devices continues to grow across various applications, including biomedical and diagnostic fields. These factors have solidified the segment's position in the global microfluidics market.

Geographical Analysis

North America is expected to hold a significant position in the global microfluidics market share

North America holds a substantial position in the global microfluidics market and is expected to hold most of the market share.

The growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions significantly drives the demand for innovative diagnostic tools. Microfluidics technology plays a crucial role in addressing this need by enabling efficient monitoring and management of these diseases through rapid testing and personalized medicine approaches.

North America is recognized for its well-developed healthcare system, which significantly supports the integration and adoption of advanced technologies such as microfluidics. This robust infrastructure facilitates the implementation of microfluidic devices across various applications, particularly in diagnostics and drug delivery.

Moreover, in this region, a major number of key players' presence, government initiatives & regulatory support, and technological advancements, & investments would propel this microfluidics market growth. For instance, in May 2024, Takara Bio USA, Inc. introduced the Lenti-X Transduction Sponge, an innovative product designed to enhance lentivirus-mediated gene delivery. This innovative tool is notable for being the first dissolvable microfluidic transduction enhancer on the market, streamlining in vitro gene delivery processes. Thus, the above factors are consolidating the region's position as a dominant force in the global microfluidics market.

Asia Pacific is growing at the fastest pace in the global microfluidics market share

Asia Pacific holds the fastest pace in the global microfluidics market and is expected to hold most of the market share.

The prevalence of chronic diseases, including diabetes, cancer, and cardiovascular conditions, is on the rise in the Asia-Pacific region. This trend necessitates the development of efficient diagnostic instruments and treatment options, further propelling the demand for microfluidic technologies. The need for rapid, cost-effective diagnostic tools and precision healthcare solutions is a major driver of the microfluidics market. Devices such as lab-on-a-chip and point-of-care testing systems are essential for delivering quick diagnostics, which are particularly valuable in managing chronic diseases and infectious conditions.

Innovations in microfluidic technology are expanding their applications across various sectors, including healthcare, environmental monitoring, and food safety. These advancements enable more efficient biochemical analyses using smaller sample sizes, making them ideal for clinical diagnostics and pharmaceutical research. Rapid advancements in healthcare infrastructure across countries like China, India, and Japan are facilitating the adoption of advanced medical technologies. Increased investment in biotechnology and medical research is establishing the Asia-Pacific region as a hub for microfluidics development.

Microfluidics plays a significant role in personalized medicine by enabling tailored treatment strategies based on individual patient profiles. This focus on personalized healthcare solutions is boosting the demand for microfluidic devices that can support such applications. Many governments in the Asia-Pacific region are implementing policies that promote research and development in microfluidics. This support fosters innovation and accelerates market growth by providing financial assistance and creating favorable regulatory environments.

Furthermore, key players in the industry product launches that would drive this microfluidics market growth in the region. For instance, in February 2023, Mumbai-based Amar Equipment launched NanoMake, which is recognized as India's first microfluidic platform aimed at accelerating preclinical development for mRNA vaccines and nano-formulations. This significant announcement was made during the Biosimilar Workshop held at the Institute of Chemical Technology, one of the largest gatherings of biopharmaceutical researchers in India. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global microfluidics market.

Competitive Landscape

The major global players in the microfluidics market include Thermo Fisher Scientific Inc., PerkinElmer, Agilent Technologies, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Standard BioTools (Fluidigm Corporation), Merck KGaA, Sphere Fluidics., uFluidix, and Emulate Inc. among others.

Key Developments

• In November 2024, LumiraDx introduced a Rapid Microfluidic Immunoassay C-Reactive Protein (CRP) Test aimed at addressing antimicrobial resistance (AMR) in India. This innovative test is designed to provide quick and accurate results, enabling healthcare providers to make informed decisions regarding the use of antibiotics.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global microfluidics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Material
• 3.3. Snippet by Application
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Point-of-Care Testing (POCT)
  • 4.1.2. Restraints
    • 4.1.2.1. High Research and Development Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Microfluidic-Based Devices*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Microfluidic Components
  • 6.3.1. Microfluidic Chips
  • 6.3.2. Micro Pumps
  • 6.3.3. Microneedles
  • 6.3.4. Others
• 6.4. Others

7. By Material

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 7.1.2. Market Attractiveness Index, By Material
• 7.2. Polymer*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Silicon
• 7.4. Glass
• 7.5. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Drug Delivery*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Point-of-Care Diagnostics
• 8.4. Pharmaceutical and Biotechnology Research:
  • 8.4.1. High-throughput Screening
  • 8.4.2. Proteomics
  • 8.4.3. Genomics
  • 8.4.4. Cell-based Assays
  • 8.4.5. Capillary Electrophoresis
  • 8.4.6. Others
• 8.5. Clinical Diagnostics
• 8.6. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals and Diagnostic Centers*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Academic and Research Institutes
• 9.4. Pharmaceutical and Biotechnology Companies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Thermo Fisher Scientific Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. PerkinElmer
• 12.3. Agilent Technologies, Inc.
• 12.4. Illumina, Inc.
• 12.5. Bio-Rad Laboratories, Inc.
• 12.6. Standard BioTools (Fluidigm Corporation)
• 12.7. Merck KGaA
• 12.8. Sphere Fluidics.
• 12.9. uFluidix
• 12.10. Emulate Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us